Showing 1 - 10 of 132
<Emphasis Type="Bold">Background: The PCI-CURE (Percutaneous Coronary Intervention-Clopidogrel in Unstable Angina to Prevent Recurrent Events) and CREDO (Clopidogrel for the Reduction of Events During Observation) studies have demonstrated that, in addition to aspirin, pre-treatment with clopidogrel followed by...</emphasis>
Persistent link: https://www.econbiz.de/10011001669
Background:Background: Preference-based health state utilities are required for many health economic evaluations. When the direct evidence of such is lacking and only condition-specific scores are available, establishing a 'mapping' relationship between instruments can be useful. Abstract:...
Persistent link: https://www.econbiz.de/10010558524
Persistent link: https://www.econbiz.de/10003789956
Persistent link: https://www.econbiz.de/10013488208
Background: The PCI-CURE (Percutaneous Coronary Intervention-Clopidogrel in Unstable Angina to Prevent Recurrent Events) and CREDO (Clopidogrel for the Reduction of Events During Observation) studies have demonstrated that, in addition to aspirin, pre-treatment with clopidogrel followed by...
Persistent link: https://www.econbiz.de/10005449235
Persistent link: https://www.econbiz.de/10009404216
Persistent link: https://www.econbiz.de/10010826471
When considering the cost-effectiveness categorization as proposed by the Swedish National Board of Health and Welfare, clopidogrel appears to be associated with costs per QALY that range from intermediate in the total CAPRIE population to low in high-risk atherosclerotic patients. </AbstractSection> Copyright...
Persistent link: https://www.econbiz.de/10011000730
Treatment with RLAI is suggested to result in improved QALYs combined with cost savings compared with haloperidol LAI among the Swedish, high-risk non-compliant schizophrenia patient population. In the general schizophrenia population, RLAI also resulted in positive incremental QALYs and cost...
Persistent link: https://www.econbiz.de/10011000765
The cost-effectiveness estimates presented in this article support the NICE guidelines for the use of antiplatelets for the prevention of cardiovascular events. Based on these pharmacoeconomic data alone, aspirin should be prescribed for primary or secondary prevention among patients at high...
Persistent link: https://www.econbiz.de/10011001710